

September 20, 2024

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received a final assessment order passed by the assessment unit under section 143(3) read with section 144C(13) and 144(B) of the Income Tax Act, 1961 (the Act) for assessment year 2021-22, on September 19, 2024.

The captioned final assessment order is a subsequent development to the draft order received earlier, which was disclosed to the stock exchanges vide our letter dated December 22, 2023.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You

For AstraZeneca Pharma India Limited

Manasa R
Company Secretary

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the opposing party	Assessment Unit, Income tax department
2.	Brief details of dispute/litigation	Company has received a final assessment order passed by the assessment unit under section 143(3) read with section 144C(13) and 144(B) of the Income Tax Act, 1961 (the Act) for assessment year 2021-22 wherein adjustment on the legacy transfer pricing issues has been made under section 92CA(3) of the Act along with few corporate tax issues.
3.	Court/tribunal/agency where the litigation is filed	The matter will be challenged before the Income-tax Appellate Tribunal (ITAT) by filing an appeal.
4.	Expected financial implications, if any, due to compensation, penalty etc.	Matter will be suitably challenged in due course. The expected overall financial implication cannot be determined at this stage.
5.	Quantum of claims, if any	Rs. 14.08 crores (approx.) excluding interest and penalty.